<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178136</url>
  </required_header>
  <id_info>
    <org_study_id>LSBCIGO-1-DH3-2016-12</org_study_id>
    <nct_id>NCT03178136</nct_id>
  </id_info>
  <brief_title>HR-HPV Multi-site Opportunistic Screening in Liaoning, China</brief_title>
  <official_title>HR-HPV Multi-site Opportunistic Screening in Liaoning, China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Min Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenyang women's and children's hostipal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dandong women's and children's hostipal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The second hospital of Chaoyang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's and children's hospital of Yingkou City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer hospital of Anshan City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Dalton Biosciences,LtD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is universally accepted that the persistent infection of high-risk human
      papillomavirus(HR-HPV) is the cause of cervical intraepithelial neoplasias and cancer. Some
      researches indicate that the virus load may relate the extent of the disease. The objective
      of the study is to detect the virus load of 14 types HR-HPV among the participants, using a
      new HPV DNA hybrid capture technology,sequentially find the diagnostic significance of virus
      load of HPV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer is the most common malignancy in women, the persistent infection of high-risk
      human papillomavirus(HR-HPV) is the definite cause,especially the infection of human
      papillomavirus 16/human papillomavirus 18(HPV16/HPV18). Some researches indicate the virus
      load may relate the extent of the disease, but the sample capacity is not enough to receive a
      conclusive conclusion. And a specific quantity or a range of virus load which closely relates
      to cervical intraepithelial neoplasia 2(CIN2) or worse is not studied. The aim of the study
      is to prove the association between the virus load and development of cervical
      intraepithelial neoplasias by detecting 14 types HR-HPV, and find the specific quantitative
      value or the range to assist physician to diagnose.

      A detect reagent named Dalton hybrid 3(DH3) is used in the study, the mechanism of which is
      HPV DNA hybrid capture technology, the experimental process include seven steps,
      denaturation, hybridization, the formation of DNA-RNA heterozygote, capture, detect, rinse
      panel, read data.

      Study design: The organizations of the study contain ten hospitals in Liaoning province in
      China,patients accord with inclusion criteria(N=10000) sign informed consent and fill out a
      information form. Gynecologist collect cervical cell with sampling instrument. Detecting the
      virus load of HPV16/HPV18 and other 12 types HR-HPV, the positive result is cut-off
      â‰¥1.0pg/ml, HPV16/HPV18(+) need colposcopy. The abnormal result of colposcopy requires biopsy,
      the participant who has abnormal result of biopsy need operative treatment. Follow-up
      observation of all participants lasting 5 years are required.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>virus load</measure>
    <time_frame>1 day</time_frame>
    <description>virus load of 14 types HR-HPV</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>case group</arm_group_label>
    <description>There is no intervention in case group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>The control group as the contrast for case group.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cervical cell
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who are voluntary to accept screening with sexual life between the age of 25
        to 65 are the target population of the study.

        The population who with uterectomy, cancer, other serious illness, physical examination are
        exclusive, the pregnant women are not exclusive.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patients who are voluntary to accept screening with sexual life

        Exclusion Criteria:

        uterectomy, cancer, other serious illness, physical examination(pregnant women are not
        exclusive)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Wang</last_name>
    <role>Study Director</role>
    <affiliation>Shengjing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer hospital of Anshan City</name>
      <address>
        <city>Anshan</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second hospital of Chaoyang City</name>
      <address>
        <city>Chaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian obstetrics and gynaecology hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and children's hospital of Yingkou City</name>
      <address>
        <city>Yingkou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang women's and children's hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Lioaning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003 Sep;201(1):1-6. Review.</citation>
    <PMID>12950011</PMID>
  </reference>
  <reference>
    <citation>Vorsters A, Van Keer S, Biesmans S, Hens A, De Coster I, Goossens H, Ieven M, Van Damme P. Long-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing. Int J Mol Sci. 2016 May 17;17(5). pii: E750. doi: 10.3390/ijms17050750.</citation>
    <PMID>27196899</PMID>
  </reference>
  <results_reference>
    <citation>Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, Burton K, Reed NS, Graham SV. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer. 2017 Mar 1;140(5):1134-1146. doi: 10.1002/ijc.30523.</citation>
    <PMID>27864932</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>January 1, 2019</last_update_submitted>
  <last_update_submitted_qc>January 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Min Wang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>HR-HPV opportunistic screening</keyword>
  <keyword>virus load</keyword>
  <keyword>multi-site</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

